MMM — Q1 2026 Financial Report Analysis

Headline: a 40% drop in reported earnings that had almost nothing to do with the business

3M's first quarter of 2026 (the three months to March 31, 2026) produced two numbers that point in opposite directions. Reported ("GAAP") earnings per share — the profit attributable to each share of stock, calculated under standard US accounting rules — fell 40% to $1.23. Adjusted earnings per share, which strips out items management treats as one-offs, rose 14% to $2.14.

The entire gap is explained by items outside the manufacturing business. The largest by far: 3M still owns about 15% of Solventum, the health care business it spun off in 2024, and it has to run the change in that stake's market value through its income statement every quarter. Solventum's share price fell during Q1 2026 and rose during Q1 2025, producing a $356 million charge this year against a $343 million gain last year — a $699 million year-over-year swing, or $1.30 per share, with no cash changing hands. Strip that out and the underlying operating picture was modestly better, not dramatically worse.

Source: 3M Form 10-Q for the quarter ended March 31, 2026 (filed April 21, 2026) and the Q1 2026 earnings release (Exhibit 99.1 to the Form 8-K filed the same day). "bps" = basis points; 100 bps = 1 percentage point.

Sales grew 1.3%, but only because of the dollar

Sales rose $76 million. The components of that change, disclosed in the MD&A, matter more than the total:

Currency translation — the effect of converting sales made in euros, yen and other currencies back into a weaker US dollar — added 2.8 percentage points. Without it, 3M's sales would have fallen. That reported organic decline is itself distorted: 3M finished exiting its PFAS-chemicals manufacturing at the end of 2025, and those products contributed $174 million of sales in Q1 2025 against only $27 million in Q1 2026. Excluding that deliberate exit, adjusted organic sales grew 1.2% — real but slight growth, well below the ~3% full-year pace management is guiding to.

The regional split shows how much of the headline is currency:

EMEA is the clearest case of a headline number and its driver pointing opposite ways: sales in dollars grew 6.7%, the fastest of the three regions, while the underlying volume-and-price business shrank 3.2%. A 9.9-point currency tailwind did all the work. The Americas — 52% of company sales — declined on both measures.

Where the reported margin gain actually came from

Operating margin — the share of each sales dollar left after the costs of making and selling the product, before interest and tax — jumped 230 basis points to 23.2% on a reported basis. That is not an operating improvement of that size.

The swing item is litigation. 3M books its respirator/asbestos, Combat Arms Earplugs (CAE) and PFAS-related legal costs, net of what it recovers from insurers, as a "special item" inside Corporate. In Q1 2026 the company recorded $277 million of insurance recovery benefits across those matters, which was enough to turn the line into a net $170 million benefit to operating income — against a $74 million net cost a year earlier. That $244 million swing is visible in the SG&A line, which fell from $945 million to $744 million (15.9% of sales to 12.3%) even as sales grew.

Running the other way were $126 million of costs tied to the exited PFAS product line (versus $38 million last year) and $66 million of "transformation" costs — a restructuring program begun in Q3 2025 to redesign 3M's manufacturing, distribution and back-office footprint, under which management approved a further $44 million pre-tax charge, mostly severance, during Q1 2026.

Net of all special items, adjusted operating income was $1,426 million versus $1,358 million, up 5.0%, and the adjusted margin improved 30 basis points to 23.8%. Management attributes that narrower gain to volume growth, productivity work and favorable currency, partly offset by three specific drags it names: tariffs, "cost dis-synergies" (overhead that used to be spread across the PFAS business and the spun-off Solventum and now sits on a smaller base), and spending on growth initiatives.

One more disclosure to keep in mind when comparing to older 3M reports: effective this quarter, 3M moved manufactured-PFAS-product activity out of Transportation & Electronics and respirator/asbestos litigation costs out of Safety & Industrial, putting both in Corporate. Prior-period segment figures have been restated on the same basis, so the comparisons below are like-for-like, but they will not match what 3M published for Q1 2025 at the time.

Segments: industrial is carrying the quarter

Safety and Industrial was the only segment growing on both sales and margin. Growth came from electrical markets, industrial adhesives and tapes, abrasives, personal safety and automotive aftermarket; roofing granules and industrial specialties declined. Operating income rose 11.0% on 6.8% dollar sales growth, so margin expanded a point — though note that 3.6 of those 6.8 points were currency, meaning income grew roughly twice as fast as the underlying business did.

Transportation and Electronics was flat underneath (organic -0.3%) with a genuine split inside it: semiconductor, data center, aerospace and commercial branding grew, while consumer electronics and automotive end markets were weak. Margin was essentially unchanged at 21.6%.

Consumer is the weak point. Organic sales fell 1.3% and it was the only segment whose margin declined, to 19.2%. 3M attributes this to weak US discretionary spending, with home and auto care growing while packaging/expression and home improvement fell. Tariffs, growth investments and the PFAS-exit cost drag more than offset productivity gains here.

Corporate sales — now the home of residual PFAS product activity — fell from $269 million to $121 million, which is where most of the reported organic sales decline sits.

Cash: a large buyback funded out of the balance sheet

Cash from operations was $574 million, against an outflow of $79 million a year ago. The $653 million improvement is not operational either: it reflects lower net cash going out the door on PFAS environmental liabilities and the CAE settlement, because roughly $0.3 billion of insurance recoveries came back in against about $0.3 billion of payments. Capital spending was $225 million, and 3M still expects about $1.1 billion for the full year. The company reported adjusted free cash flow — operating cash left after capital spending, on its adjusted basis — of $0.5 billion.

Against that, 3M returned $2.4 billion to shareholders: $2.0 billion of share buybacks (up from $1.3 billion a year ago) and $412 million of dividends, after a 7% dividend increase to $0.78 per share declared in February. Spending $2.4 billion out of $0.6 billion of operating cash flow drew down the balance sheet — cash, equivalents and marketable securities fell from $5.9 billion at December 31, 2025 to $4.2 billion. About $2.7 billion remained under the $7.5 billion repurchase authorization at quarter-end. The buyback is doing visible work on EPS: the diluted share count is down 2.7% year over year.

Takeaway: Almost every large number in this quarter — the 40% EPS decline, the 230 bps reported margin gain, the 1.3% sales growth, the $653 million cash flow improvement — is driven by something other than 3M selling more product at a better price. Mark-to-market on the Solventum stake, insurance recoveries on legacy litigation, and a weak dollar account for the swings in all four. The business underneath grew adjusted organic sales 1.2% and adjusted operating margin 30 bps, which is a company improving slowly, not inflecting.

Outlook: guidance reiterated, and the maths get harder from here

3M left its full-year 2026 guidance unchanged:

CEO William Brown called it "a good start to the year" and said the company remains "confident in achieving our 2026 guidance."

Two things about that guidance are worth watching. First, Q1's adjusted organic growth of 1.2% is well short of the ~3% full-year target, so the remaining quarters need to run meaningfully above 3% — and the weak spots this quarter (US consumer discretionary, automotive, consumer electronics, the Americas as a whole) are end markets 3M does not control. Second, adjusted EPS grew 14% while adjusted operating income grew only 5%. The difference came from a lower adjusted tax rate (17.5% versus 20.9%, which management itself attributes partly to "tax timing") and the 2.7% smaller share count — roughly $0.09 and $0.06 per share respectively by our arithmetic on the disclosed figures. Tax timing reverses; buybacks require cash that came out of a shrinking securities balance this quarter. Neither is a durable source of the earnings growth rate implied by $8.50–$8.70.

The legal overhang also cuts both ways. Insurance recoveries flattered this quarter's reported profit and cash flow, but they are recoveries against liabilities 3M has already recognized, and the 10-Q is explicit that for the Aearo respirator/asbestos matters it "cannot estimate the amount or range of amounts by which Aearo's liabilities may exceed recorded accruals." The PFAS docket continued to expand during the quarter, with new suits filed in Georgia and the City of Fresno case transferred into the AFFF multidistrict litigation in April 2026. A quarter where litigation is a net credit to earnings is not evidence the issue is behind the company.